- Angiotensin acetate
-
- $0.00 / 1g
-
2025-05-21
- CAS:58-49-1
- Min. Order: 1g
- Purity: 98%min
- Supply Ability: 1000g
- Angiotensin acetate
-
- $0.00 / 25KG
-
2025-05-16
- CAS:58-49-1
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 50000KG/month
- Angiotensin acetate
-
- $0.10 / 1kg
-
2025-04-22
- CAS:58-49-1
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 20 tons
|
| | Angiotensin acetate Basic information |
| Product Name: | Angiotensin acetate | | Synonyms: | [VAL5]-ANGIOTENSIN II;[VAL5] ANGIOTENSIN II HUMAN;ASP-ARG-VAL-TYR-VAL-HIS-PRO-PHE;DRVYVHPF;L-ASP-ARG-VAL-TYR-VAL-HIS-PRO-PHE;H-ASP-ARG-VAL-TYR-VAL-HIS-PRO-PHE-OH;[val5]-angiotensin ii acetate hydrate;Angiotensin acetate | | CAS: | 58-49-1 | | MF: | C49H69N13O12 | | MW: | 1032.15 | | EINECS: | | | Product Categories: | | | Mol File: | 58-49-1.mol |  |
| | Angiotensin acetate Chemical Properties |
| storage temp. | -20°C | | form | powder | | density | 1.45±0.1 g/cm3(Predicted) | | pKa | 3.56±0.10(Predicted) | | color | White to off-white | | Water Solubility | Water : ≥ 257.5 mg/mL (249.48 mM) | | Sequence | H-Asp-Arg-Val-Tyr-Val-His-Pro-Phe-OH | | InChIKey | JVCJXRGXGITABA-IAQGTVMASA-N | | CAS DataBase Reference | 58-49-1 |
| | Angiotensin acetate Usage And Synthesis |
| Uses | Angiotensin acetate is a biologically active peptide and a derivative of [5-?valine]?angiotensin II. | | Definition | ChEBI: Val(5)-angiotensin II is an angiotensin II. | | Biochem/physiol Actions | Angiotensin II analog that is an agonist AT1 angiotensin receptors. | | in vivo | By day 12, systolic blood pressure (SBP) increases significantly in Angiotensin II 5-valine infused rats (197±7 mm Hg).The development of hypertension in ANG II infused rats is prevented by losartan treatment. Blood and kidney samples are harvested, subjected to HPLC to separate Angiotensin II 5-valine (exogenous) from Ile5-ANG II (endogenous) and the fractions are measured by radioimmunoassay. In the Angiotensin II 5-valine infused rats treated with losartan, total plasma ANG II levels are elevated to a greater extent than in rats not treated with losartan (289±20 v 119±14 fmol/mL). However, losartan markedly decrease by 88% the enhancement of intrarenal Val5-ANG II content that occurred in the rats infused with Val5-ANG II alone[1]. |
| | Angiotensin acetate Preparation Products And Raw materials |
|